Drilldown: Medicines
Medicines > halflife 
:
1-1.5 hours'"`UNIQ--ref-00000DE3-QINU`"' or
Not applicable (electrolyte and buffer) or
~27 days
:
1-1.5 hours'"`UNIQ--ref-00000DE3-QINU`"' or
Not applicable (electrolyte and buffer) or
~27 days Use the filters below to narrow your results.
generic:
brand:
classes:
mechanism:
None (1) ·
Humanized IgG1 monoclonal antibody binding CGRP peptide; IV infusion enables fastest onset of any CGRP mAb (1) ·
Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) ·
'"`UNIQ--vote-00000016-QINU`"' Bicarbonate is not benign: high-volume use produces hypernatremia, metabolic alkalosis, hypokalemia, and (in arrest) paradoxical intracellular acidosis'"`UNIQ--ref-00000017-QINU`"'. (1)
uses:
Preventive treatment of migraine in adults (1) ·
Preventive treatment of migraine in adults; episodic cluster headache (1) ·
'"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"' (1) ·
'"`UNIQ--vote-00000DDF-QINU`"', '"`UNIQ--vote-00000DE0-QINU`"', '"`UNIQ--vote-00000DE1-QINU`"', '"`UNIQ--vote-00000DE2-QINU`"' (1)
starting dose:
0.5-1 mg PO/IV once or twice daily; titrate to clinical response. Approximate equipotency: bumetanide 1 mg ≈ furosemide 40 mg ≈ torsemide 20 mg (1) ·
100 mg IV every 3 months; may increase to 300 mg IV every 3 months (1) ·
IV: 1 mEq/kg bolus in arrest indication, then titrated to ABG and clinical status; PO: 325-2000 mg up to QID as antacid (1) ·
Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1)
preparations:
fda max:
routes:
onset:
duration:
halflife: (Click arrow to add another value)
bioavailability:
pregnancy:
Error in "where" parameter: the string "--" cannot be used within #cargo_query.
There are no results for this report.